Drug
Ery974
Ery974: highest development phase Phase 1, developed by Chugai. 2 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Chugai
Trials
| Drug | Phase | Indication |
|---|---|---|
| ERY974 NCT02748837 | Phase 1 | Solid Tumors |
| ERY974 NCT05022927 | Phase 1 | Hepatocellular Carcinoma (HCC) |
Latest
No recent events.
Follow Ery974 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.